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59 SETTING: Identification of the factors associated with disease progression could help 
60 physicians early and prospectively recognize patients at high risk of progression. 
61 OBJECTIVE: This study aims to evaluate the clinical features in disease progression among 
62 patients with COVID-19 after admission. 
63 DESIGN: This is a retrospective, multi-center cohort study. From January 10 and February 
64 29, 2020, all cases diagnosed with COVID-19 at 24 hospitals in Jiangsu province, with 
65 complete medical records were involved. The primary outcome was the disease deterioration 
66 defined as the dramatic progression from asymptomatic or mild or moderate status on 
67 admission into severe or critically ill status during 14 day’s follow-up. 
68 RESULTS: Of the 625 patients in Jiangsu, none of patients died, and 597 patients were 
69 asymptomatic or mild or moderate on admission, of which 36 (6%) experienced disease 
70 deterioration to severe or critically ill status. Disease deterioration to severe or critically ill 
71 status was associated with age, pulmonary opacity score, lymphocyte count on admission, 
72 and pandemic center Wuhan exposure.
73 CONCLUSION: Disease deterioration to severe or critically ill status was observed in 6% 
74 patients during 14 days follow-up, and was associated with age, pulmonary opacity score, 
75 lymphocyte count, and pandemic center Wuhan exposure.
76 KEY WORDS: COVID-19; coronavirus; 2019-nCoV; disease deterioration; disease 
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85 The World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) 
86 a pandemic affecting all continents on the 11th March 2020.1 During the clinical course, 
87 some patients experienced deterioration in clinical symptoms, and some cases have 
88 progressed rapidly to acute respiratory distress syndrome (ARDS), septic shock, metabolic 
89 acidosis, coagulopathy, multi-organ system failure, death, or other poor outcomes.2-4 A study 
90 on clinical course and mortality of adult inpatients with COVID-19 in Wuhan found that the 
91 mortality of severe and critically ill patients was 22% and 78%, respectively.3 Another study 
92 has reported risk factors for progression from ARDS to death in patients with COVID-19.2 
93 However, either the pattern of the disease progression from moderate or less status to 
94 severe/critically-ill status or their associates has not been fully investigated in patients with 
95 COVID-19. Assessment of patterns of disease progression and identification of factors 
96 associated with disease progression could help physicians early and prospectively recognize 
97 patients at high risk of progression and help patients avoid entering a crisis phase linked to 
98 oxygen desaturation profiles. This multicenter retrospective cohort study set out to describe 
99 the occurrence of disease progression in patients with COVID-19 after admission and explore 
100 the factors associated with progression from moderate or less status to severe or critically 
101 illness.
102 Methods 
103 Study design and participants 
104 This retrospective cohort study included all the patients who met the patient inclusion and 
105 exclusion criteria. Inclusion criteria were as of February 29, 2020, all patients diagnosed with 
106 COVID-19 in Jiangsu according to diagnostic criteria of “Diagnosis and Treatment Protocol 
107 for Novel Coronavirus Pneumonia (Trial Version 7)” released by National Health 
108 Commission & National Administration of Traditional Chinese Medicine of China,5 and 
109 admitted to designated hospitals for COVID-19 treatment in Jiangsu province. The diagnosis 
110 of COVID-19 was based on epidemiological history, clinical manifestations, imaging 
111 manifestations of pneumonia in computer tomography (CT) scans, and laboratory 
112 confirmation (positive real-time reverse transcription–polymerase chain reaction assays, RT-
113 PCR).5 Exclusion criteria was medical records unavailability. For patients presented to the 
114 hospital, those who had possible exposure to the Severe Acute Respiratory Syndrome 
115 Coronavirus-2 (SARS-CoV-2, the etiological agent causing COVID-19), or had no 
116 identifiable exposure but clinical or imaging manifestations would be tested for SARS-CoV-
117 2. The discharge standard was body temperature return to normal for more than 3 days, 
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118 symptoms become better if they have symptoms, and RT-PCR (throat swab samples, at least 
119 1 day for sampling interval) showed negative for 2 consecutive times.
120 Data collection and definition of variables
121 The epidemiological, clinical, laboratory, and radiologic parameters were collected on 
122 admission. Data on disease severity were available at days 1, 2, 3, 4, 5, 6, 7 and 14 after 
123 admission, except for those who were discharged, and data on mortality and hospitalization 
124 status were available until February 29, 2020. The primary outcome was disease 
125 deterioration, i.e. dramatic progression from asymptomatic or mild or moderate status on 
126 admission, to severe or critically ill status during 2 weeks follow-up. Dramatic progression in 
127 our study does not include fragile progression such as progression from asymptomatic to mild 
128 status or from mild status to moderate status, or severe status to critically ill status. Two 
129 attending physicians adjudicated the disease severity (asymptomatic, mild, moderate, severe, 
130 or critically ill). Asymptomatic infection was defined as the absence of clinical symptoms but 
131 a positive nucleic acid test result. Mild disease was defined as having mild clinical symptoms 
132 and the absence of imaging manifestations of pneumonia in CT scans. Moderate disease was 
133 defined as the presence of fever, respiratory tract symptoms or other symptoms and imaging 
134 manifestations. Severe disease was defined as the presence of at least one of the following 
135 items: respiratory distress, respiratory rate ≥ 30 beats/min; oxygen saturation in resting state 
136 (SpO2) ≤ 93%; or arterial blood oxygen partial pressure (PaO2) / fraction of inspired oxygen 
137 (FiO2) ≤ 300 mmHg (1 mmHg = 0.133kPa). Critically ill was defined as having respiratory 
138 failure requiring mechanical ventilation, shock or combined organ failure requiring intensive 
139 care unit (ICU) monitoring and treatment.
140 All of the patients in Jiangsu have taken a high-resolution CT of thorax examination which 
141 could truly reflect the lung lesions. CT images were assessed in a visual manner by two 
142 radiologists with more than 5 years of working experience in chest imaging. The radiologists 
143 were blinded to the patients’ information. Quadrant scores were the sum of the number of 
144 quadrants containing pulmonary opacities extending from the proximal to the distal end of 
145 the chest and had a score between 0 and 4. For pulmonary opacity, bilateral lungs were 
146 scored manually and assigned an estimated percentage of pulmonary opacity relative to the 
147 whole lung, rounded to the nearest 5%.  
148 Statistical analysis
149 A summary table was generated to present dynamic patterns of disease progression in 
150 severity at each follow-up day by three categorised disease severity groups (1= 
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151 asymptomatic/mild, 2=moderate, and 3=severe/critically ill) on admission. We also generated 
152 a table to present the disease progression to worst severity during 14-day hospitalization 
153 among COVID-19 patients. Continuous variables were reported as means ± standard 
154 deviation (SD) or median (interquartile range [IQR]) by group (patients with and without 
155 disease deterioration) and compared using Student's t-test or Mann–Whitney U test 
156 depending on their distributions. Categorical variables were summarized using frequency and 
157 percentage and compared by Chi-square/Fisher exact test. 
158 Logistic regression models were used to identify the risk factors of developing a disease 
159 deterioration. Variables that were significant at the significance level of 5% in the univariate 
160 logistic regression analysis were included in the multivariate logistic regression. Missing 
161 covariates at admission were imputed in multivariate regression model analysis with multiple 
162 imputation using a Markov Chain Monte Carlo simulation method with 10 iterations. In the 
163 logistic regression analysis, odds ratios for having a disease progression for each variable 
164 were calculated along with 95% confidence intervals (CIs). The 2-tailed P < 0.05 was 
165 considered as statistically significant for all analyses. The analyses were performed using 
166 SAS 9.4 (SAS Institute).
167 Ethics approval 
168 The study was approved by the Ethics Committee of Zhongda Hospital Affiliated to 
169 Southeast University (2020ZDSYLL013–P01 and 2020ZDSYLL019–P01). Patient informed 
170 consent was waived due to the retrospective study design.
171 Results
172 From January 10, 2020 to February 29, 2020, 721 suspected cases with possible COVID-19 
173 were admitted in 24 hospitals in Jiangsu province, China, while 90 cases were excluded 
174 because of negative RT-PCR result. 631 cases were diagnosed with COVID-19 totally. This 
175 study included 625 cases who had complete medical records (Figure 1). The median age was 
176 46 years (IQR, 32-57; range, 0.75-96 years), and 329 (52.6%) were men. No deaths were 
177 reported during this study.
178 Table S1 in the Supplement provides a table showing the dynamic patterns of disease 
179 progression by follow-up day among patients with COVID-19. On admission (day 1), overall, 
180 109 (17.4%) patients were in asymptomatic or mild status, 488 (78.1%) in moderate status, 
181 and 28 (4.5%) severe or critically ill status. Overall, changes in disease severity from 
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182 admission show an increased proportion of moderate cases deteriorating into severe or 
183 critically ill cases with 8 (1.6%) at day 2 progressively increased up to 25 (5.2%) at day 7.
184 Table 1 presents the disease progression in severity from admission to the worst severity 
185 during 14-day hospital stay among COVID-19 patients. Of the 625 patients, 83.7% (523) 
186 patients had a stable condition or became better during 14 days’ hospitalization whereas 
187 16.3% (102) patients progressed to at least one degree in disease severity. Some patients had 
188 disease deterioration, i.e. dramatic progression from asymptomatic or mild or moderate status 
189 on admission, to severe or critically ill status, during 2 weeks of hospital stay. 36 out of 597 
190 (6%) patients had dramatic progression from day 2 to 14 after admission. 
191 Compared to patients without dramatic progression (n = 561) during 14-day hospitalization, 
192 patients with dramatic progression (n = 36) were significantly older (mean [SD], 60.97 
193 [12.67] vs 42.71 [16.75]; P < .0001), were more likely to be imported cases who had a 
194 history of the pandemic center Wuhan contact (52.8% vs 34.6%; P = 0.0272), to have prior 
195 histories of hypertension (27.8% vs 13.5%; P = 0.0184), and diabetes (16.7% vs 5.3%; P = 
196 0.0057), to have lower SpO2 (mean [SD], 97.17 [1.81] vs 97.92 [1.15]; P = 0.0003), and 
197 higher CT quadrant score (median [IQR], 4.0 [0.0-4.0] vs 2.0 [0.0-4.0]; P < . 0001) and 
198 pulmonary opacity volume percentage (median [IQR], 50.0 [0.0-80.0] vs 20.0 [0.0-80.0]; P 
199 < .0001) (Table 2). Patients with disease deterioration had also significantly lower 
200 lymphocyte count (109/L) (median [IQR], 0.8 [0.2-1.5] vs 1.4 [0.3-3.6]; P < .0001) and 
201 platelet count (109/L) (median [IQR], 155.5 [92.0-236.0] vs 188.5 [51.0-530.0]; P = 0.0004) 
202 than those without. In addition, patients with disease deterioration had significantly higher 
203 level of C-reactive protein (mg/L) (median [IQR], 26.2 [0.5-250.4] vs 10.0 [0.5-208.2]; P = 
204 0.0020) and fibrinogen (g/L) (median [IQR], 4.2 [1.5-7.0] vs 3.4 [0.9-8.2]; P = 0.0175) than 
205 those without.
206 Eleven variables were selected into univariate and multivariate logistic regression analyses 
207 (Table 3). For multivariable logistic regression model, 4 variables measured at admission 
208 were identified to be independently related to the occurrence of disease: age (year) (odds ratio 
209 [OR], 1.08; 95% confidence interval [CI]: 1.04-1.12; P < 0.0001), pulmonary opacity score 
210 (per 5%) (OR, 1.30, 95% CI: 1.10-1.52; P = 0.0016), lymphocyte (109/L) (OR, 0.28, 95% CI: 
211 0.09-0.91; P = 0.0357), and imported cases (exposed to the pandemic center Wuhan) (OR, 
212 2.45, 95% CI: 1.03-5.80; P = 0.0421). 
Page 7 of 18
For Review Only
8
213 Table S2 demonstrates that oxygen was delivered to patients with disease deterioration via 
214 nasal cannulae (31 [86.1%]), simple face masks (7 [19.4%]), high-flow nasal cannulae (11 
215 [30.6%]), or prone position (6 [16.7%]). Ventilatory support was used in approximately 50% 
216 of patients with clinical progression.
217 Discussion
218 This is one of the largest study to describe disease progression in patients hospitalized with 
219 COVID-19. As of February 29, 2020, in Jiangsu, China, 625 cases with available data were 
220 included in this study. On admission to hospital, 17.4% patients had asymptomatic or mild 
221 disease, 78.1% had moderate disease, and 4.5% were severely or critically ill. During the 
222 study period (to February 29, 2020) there were no deaths; 81.6% had been discharged, and 
223 less than 1% were requiring ongoing ICU care. Jiangsu province reported no death mainly 
224 due to early recognition of high-risk and critically ill patients, early intervention, hierarchical 
225 management strategies, and reasonable allocation of materials and human resources.6
226 We found that over four-fifths of patients with COVID-19 had a stable or improving clinical 
227 course with a minority deteriorating during 14-day follow-up period. This is consistent with a 
228 previous study which found that after 2 weeks from admission, 14.1% (11) of patients had 
229 worsened status and 85.9% (67) of patients had improved or stable status.7 Several studies 
230 showed clinical deterioration may occur within two weeks after onset of illness.3,8-10 In 
231 comparison, other fatal zoonotic coronavirus diseases, severe acute respiratory syndrome 
232 (SARS) and Middle East respiratory syndrome (MERS) progress rapidly to respiratory failure 
233 and organ injury.11 Within 7 days from admission, CT shows clinical signs of 31% (4) of 
234 patients progressed, while within 14 days, 85.7% (54) of patients progressed.12-14 
235 Studies on SARS and MERS have raised a tri-phasic pattern for disease progression 
236 combined with time course of viral load. For SARS, week 1 with increasing viral load which 
237 may be related to mild symptoms; week 2 with falling viral load and severe clinical 
238 worsening and immunopathological damage as a result of overexuberant host response, rather 
239 than uncontrolled viral replication; phase 3 with either resolution of symptoms or further 
240 deterioration.15 MERS showed a similar pattern.16 For SARS-CoV-2, two correspondences 
241 reported viral loads peaked at around 5–6 days after symptom onset and a patient presented 
242 an extremely high viral load,17 and virus loads in asymptomatic patients was similar to that in 
243 symptomatic patients.18 Except for severe cases, most of the patients with COVID-19 were 
244 able to clear the virus and their disease progression fits the biphasic model well, i.e. first 
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245 phase characterized by fever and other systemic symptoms, followed by week 2 with 
246 symptoms relief.19
247 Our study reported that only 6% (36) patients experienced disease deterioration, i.e. 
248 progression from moderate or less status on admission, to severe or critically ill status within 
249 2 weeks from admission. This study showed features including symptoms and abnormal 
250 radiologic and laboratory presentation on admission may be early signs of deterioration of 
251 respiratory, immune, and coagulation system. In particular, age, pulmonary opacity score in 
252 CT, lymphocyte count, and pandemic center Wuhan exposure were independent predictors 
253 for disease progression. This is in line with a study that identified several risk factors for 
254 disease progression of COVID-19, including age, respiratory failure, and C-reactive protein.7 
255 The severity of opacity evaluated from initial CT of patients with COVID-19 was closely 
256 related to the progression of opacity presented in the subsequent CT, which are of value for 
257 monitoring disease progress.20 Older age and coagulation dysfunction were associated with 
258 progression from ARDS to death in patients with COVID-19.2 Old age and severe 
259 lymphopenia seem to be statistically significant in predicting clinical deterioration in patients 
260 with SARS.15,21 Patients who have been to Wuhan may have been exposed to a large amount 
261 of virus, so the disease may be more likely to deteriorate.
262 The progress and outcome of SARS may be associated with specific temporal patterns of 
263 development in combination with several non-specific signs and symptom complexes.22 
264 Further study suggests that clinical progression at week 2 may not be associated with 
265 uncontrolled viral replication, but with immunopathological damage.15 These evidence 
266 indirectly supported our study results: symptoms and abnormal laboratory and radiologic 
267 manifestation on admission provided early signs for short-term immunopathological damage 
268 and disease progression of COVID-19 in the near future.
269 This cohort consisted of almost all COVID-19 patients in this province with a population 
270 over 80 million and its results should be generalizable to other similar places outside Hubei 
271 province. This study also has some limitations. First, severity data were only available during 
272 the first 14-day hospital stays, and we were unable to assess the disease progression and its 
273 risk factors beyond this period. Second, the data were collected retrospectively, hence we 
274 could not assess the impact of some key predictive variables including clinical management 
275 (e.g. oxygen supportive and medical drugs treatments), viral load (e.g. the quantity of viral 
276 RNA in blood), some other laboratory parameters (e.g. LDH), and host genetic factors 
Page 9 of 18
For Review Only
10
277 because of lack of available data. As a result, observed risk factors may still be subject to 
278 unobserved confounders.
279 Conclusions
280 In this multi-center cohort of 625 patients with COVID-19 in Jiangsu province, China, we 
281 found that 16.3% of patients experienced a deterioration in their clinical condition and that 
282 6% of patients with moderate or less status deteriorated to being severe or critically ill but 
283 ultimately survived. Age, pulmonary opacity score, lymphocyte count on admission, and 
284 pandemic center Wuhan exposure were identified as the independent risk factors of disease 
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373 Table 1: Disease progression to worst severity during 2-week follow-up from admission among patients with COVID-19
374
Worst severity during 2-week follow-up Severity at admission
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Demographic Male, n(%) 309(51.8%) 21(58.3%) 288(51.3%) 0.4924
Age (year), mean(SD) 43.82(17.07) 60.97(12.67) 42.72(16.73) <.0001
Exposure type, n(%) Imported cases 384(64.3%) 19(52.8%) 194(34.6%) 0.0272
Local cases 293(49.1%) 17(47.2%) 367(65.4%)  
Types of disease onset, 
n(%)
Single onset 309(51.8%) 23(63.9%) 270(48.1%) 0.0667
Clustering onset 304(50.9%) 13(36.1%) 291(51.9%)  
Initial symptoms, n(%) Fever 388(65.0%) 28(77.8%) 360(64.2%) 0.0971
Cough 322(53.9%) 22(61.1%) 300(53.5%) 0.3730
Sputum 153(25.6%) 12(33.3%) 141(25.1%) 0.2747
Medical history, n(%) Hypertension 86(14.4%) 10(27.8%) 76(13.5%) 0.0184
Diabetes 18.87(2.05) 6(16.7%) 30(5.3%) 0.0057
Vital signs, mean(SD) Temperature 37.04(0.72) 37.26(0.89) 37.02(0.70) 0.0507
HR (bpm) 86.88(13.39) 87.39(15.73) 86.84(13.25) 0.8135
Respiratory rate (breath per 
min) 
18.87(2.05) 19.00(2.32) 18.87(2.04) 0.7051
SpO2 (%) 97.88(1.21) 97.17(1.81) 97.92(1.15) 0.0003
CT image, N, median 
(IQR)
Quadrant score (1-4) 471,2.0(0.0-4.0) 33,4.0(0.0-4.0) 438,2.0(0.0-4.0) <.0001
Pulmonary opacity (%) 471,20.0(0.0-80.0) 33,50.0(0.0-80.0) 438,20.0(0.0-80.0) <.0001
Lab test, N, median (IQR) Lymphocyte (109/L) 481,1.3(0.2-3.6) 28,0.8(0.2-1.5) 453,1.4(0.3-3.6) <.0001
Platelet (109/L) 472,184.5(51.0-530.0) 26,155.5(92.0-236.0) 446,188.5(51.0-530.0) 0.0004
C-reactive protein (mg/L) 455,10.0(0.5-250.4) 25,26.2(0.5-250.4) 430,10.0(0.5-208.2) 0.0020
Fibrinogen (g/L) 473,3.4(0.9-8.2) 30,4.2(1.5-7.0) 443,3.4(0.9-8.2) 0.0175
378
379 * The primary outcome was disease deterioration, i.e. dramatic progression from asymptomatic or mild or moderate status on 
380 admission, to severe or critically ill status during 2 weeks follow-up. 









387 Table 3: Factors associated with disease progression in patients with COVID-19: Results from logistic regression analysis (N=597)
388






Age (year) 1.08(1.05,1.11) <.0001 33.0 1.08(1.04,1.12) <.0001 17.1
Pulmonary opacity (per 5%) 1.36(1.24,1.49) <.0001 41.7 1.32(1.12,1.57) 0.0015 10.4
Lymphocyte (109/L) 0.06(0.02,0.18) <.0001 23.6 0.28(0.09,0.91) 0.0357 4.5
Imported 2.11(1.07,4.16) 0.0302 4.7 2.45(1.03,5.80) 0.0421 4.1
SpO2 (per 5%) 0.14(0.04,0.41) 0.0004 12.4 0.31(0.07,1.33) 0.1147 2.5
Platelet (109/L) 0.99(0.98,0.99) 0.0012 10.6 1.00(0.99,1.00) 0.3187 1.0
Diabetes 3.54(1.37,9.16) 0.0091 6.8 1.84(0.49,6.93) 0.3685 0.8
Quadrant score (1-4) 2.45(1.64,3.67) <.0001 19.0 0.83(0.47,1.47) 0.5275 0.4
Fibrinogen (g/L) 1.54(1.16,2.04) 0.0029 8.9 0.91(0.59,1.41) 0.6871 0.2
C-reactive protein (mg/L) 1.01(1.01,1.02) 0.0002 13.7 1.00(0.99,1.01) 0.7880 0.1
Hypertension 2.99(1.41,6.33) 0.0043 8.2 0.89(0.33,2.40) 0.8138 0.1
389
390 * Univariate analysis is based on the complete cases without missing value.
391 ** Multivariate analysis is based on imputed values for missing data in Quadrant score, Pulmonary opacity score, WBC Count, 
392 Lymphocyte, Platelet, C-reactive protein, Fibrinogen, using multiple imputation method.

























415 Figure 1: Study flow diagram
416
721 suspected cases with possible COVID-19, 
admitted in 24 hospitals in Jiangsu province from 
January 10, 2020 to February 29, 2020
625 cases included in the analysis 
597 cases with asymptomatic or mild or moderate 
presentation included for primary outcome analysis
90 excluded due to negative RT-PCR test results 
631 cases with confirmed COVID-19 
6 excluded due to missing medical records 
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Table S1: Disease progression by day among patients with COVID-19 
 
 Disease severity at Day 1  
Day Statistics Asymptomatic/Mild Moderate 
Severe/Critically 
ill All 
Day 2 n 109 488 28 625 
 Asymptomatic or mild 101(92.7%) 0(0.0%) 0(0.0%) 101(16.2%) 
 Moderate 7(6.4%) 480(98.4%) 0(0.0%) 487(77.9%) 
 Severe or critically ill 1(0.9%) 8(1.6%) 28(100%) 37(5.9%) 
Day 3 n 109 488 28 625 
 Asymptomatic or mild 90(82.6%) 6(1.2%) 0(0.0%) 96(15.4%) 
 Moderate 17(15.6%) 469(96.1%) 0(0.0%) 486(77.8%) 
 Severe or critically ill 2(1.8%) 13(2.7%) 28(100%) 43(6.9%) 
Day 4 n 109 488 28 625 
 Asymptomatic or mild 83(76.1%) 3(0.6%) 0(0.0%) 86(13.8%) 
 Moderate 24(22.0%) 465(95.3%) 0(0.0%) 489(78.2%) 
 Severe or critically ill 2(1.8%) 20(4.1%) 28(100%) 50(8.0%) 
Day 5 n 109 488 28 625 
 Asymptomatic or mild 77(70.6%) 8(1.6%) 0(0.0%) 85(13.6%) 
 Moderate 31(28.4%) 458(93.9%) 1(3.6%) 490(78.4%) 
 Severe or critically ill 1(0.9%) 22(4.5%) 27(96.4%) 50(8.0%) 
Day 6 n 105 481 28 614 
 Asymptomatic or mild 57(54.3%) 15(3.1%) 0(0.0%) 72(11.7%) 
 Moderate 48(45.7%) 443(92.1%) 4(14.3%) 495(80.6%) 
 Severe or critically ill 0(0.0%) 23(4.8%) 24(85.7%) 47(7.7%) 
Day 7 n 105 481 28 614 
 Asymptomatic or mild 76(72.4%) 20(4.2%) 0(0.0%) 96(15.6%) 
 Moderate 29(27.6%) 436(90.6%) 6(21.4%) 471(76.7%) 
 Severe or critically ill 0(0.0%) 25(5.2%) 22(78.6%) 47(7.7%) 
Day 14 n 65 328 24 417 
 Asymptomatic or mild 35(53.8%) 50(15.2%) 1(4.2%) 86(20.6%) 
 Moderate 30(46.2%) 260(79.3%) 10(41.7%) 300(71.9%) 
 Severe or critically ill 0(0.0%) 18(5.5%) 13(54.2%) 31(7.4%) 
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Table S2: Clinical management and outcome of patients with COVID-19 during hospital stay 
 
 Disease progression, n(%)  







Supportive treatments Inotropic and vasoconstrictive agents 4(11.1%) 0(0.0%) 4(0.7%) <.0001 
 Nasal cannula 31(86.1%) 168(29.9%) 199(33.3%) <.0001 
 Mask 7(19.4%) 2(0.4%) 9(1.5%) <.0001 
 High-flow nasal cannula oxygen therapy 11(30.6%) 1(0.2%) 12(2.0%) <.0001 
 Non-invasive ventilation 16(44.4%) 0(0.0%) 16(2.7%) <.0001 
 Intermittent mandatory ventilation 3(8.3%) 0(0.0%) 3(0.5%) 0.0002 
 Prone position 6(16.7%) 1(0.2%) 7(1.2%) <.0001 
Medical drugs Chinese medicine 17(47.2%) 69(12.3%) 86(14.4%) <.0001 
 Immunoglobulin 27(75.0%) 106(18.9%) 133(22.3%) <.0001 
 Interferon 25(69.4%) 456(81.3%) 481(80.6%) 0.0857 
 Antioxidants 15(41.7%) 117(20.9%) 132(22.1%) 0.0063 
 Glucocorticoid 30(83.3%) 90(16.0%) 120(20.1%) <.0001 
 Thymosin 22(61.1%) 101(18.0%) 123(20.6%) <.0001 
 Neurotrophic drugs 13(36.1%) 81(14.4%) 94(15.7%) 0.0017 
 Any antibiotics 33(91.7%) 277(49.4%) 310(51.9%) <.0001 
 Any antivirals 36(100%) 516(92.0%) 552(92.5%) 0.0995 
Clinical outcome Death 0(0.0%) 0(0.0%) 0(0.0%) NC 
 ICU 19(52.8%) 1(0.2%) 20(3.4%) <.0001 
 Shock 0(0.0%) 0(0.0%) 0(0.0%) NC 
 Respiratory failure 31(86.1%) 1(0.2%) 32(5.4%) <.0001 
 Renal failure 1(2.8%) 0(0.0%) 1(0.2%) 0.0603 
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